Flamel Technologies (FLML) Announces U.S. Launch of Akovaz
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Flamel Technologies (NASDAQ: FLML) announced the launch of Akovaz™, its formulation of ephedrine sulfate for injection, which received approval from the U.S. Food and Drug Administration (FDA) on April 29, 2016. Ephedrine sulfate (50 mg/mL) is a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings.
"I am pleased to announce the launch of Akovaz, the first version of ephedrine sulfate to be approved by the FDA. The market size of ephedrine sulfate is the largest yet from our portfolio of previously unapproved products. In total, we estimate the market volume to be somewhere in the range of seven million vials per year when factoring in sales to repackaging companies. There is currently one unapproved manufacturer of ephedrine sulfate with whom we expect to share the market," said Mike Anderson, Flamel's Chief Executive Officer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XL Group (XL) Announces Senior Management Changes Related to Realigned P&C Operating Model
- Providence & Worcester (PWX) Receives Shareholder Approval of Genesee & Wyoming (GWR) Deal
- Intrexon's (XON) Oxitec Large Mosquito Production Facility in Brazil
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!